Genomic Vision Announces New Financing Line with Winance, Subject to Prior Approval of the Company’s Shareholders

Bagneux (France) – Genomic Vision (FR0011799907 – GV – the “Company”), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the implementation of a new financing line with Winance providing for the provision, subject to the prior approval of the Company’s shareholders and the conditions for drawing down each tranche (in particular that the share price is not lower than the nominal value), of a maximum of 15 financing tranches of €2 million each, i.e. up to €30 million. This financing line is intended to enable the Company to finance its activities and development over at least the next three years.